-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Chloroquine-[d5] Diphosphate
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/1854126-42-3.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 1854126-42-3 |
| Description | Chloroquine-[d5] Diphosphate, is the labelled analogue of Chloroquine Diphosphate. Chloroquine phosphate is an antimalarial drug and weak intercalating agent. It inhibits TLR signalling in plasmacytoid dendritic cells (pDCs). It has been used in emergency of COVID-19. |
Product Information
| Synonyms | Chloroquine D5 Diphosphate |
| IUPAC Name | 4-N-(7-chloroquinolin-4-yl)-1-N-ethyl-1-N-(1,1,2,2,2-pentadeuterioethyl)pentane-1,4-diamine;phosphoric acid |
| Molecular Weight | 520.9 |
| Molecular Formula | C18H21D5ClN3D5.2H3O4P |
| Canonical SMILES | CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl.OP(=O)(O)O.OP(=O)(O)O |
| InChI | InChI=1S/C18H26ClN3.2H3O4P/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18;2*1-5(2,3)4/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21);2*(H3,1,2,3,4)/i1D3,4D2;; |
| InChIKey | QKICWELGRMTQCR-DSJRPQEBSA-N |
| Purity | > 98% |
| Solubility | PBS (pH 7.2): 10 mg/ml |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and Metabolic profiles of drugs. |
| Target | Parasite; Autophagy; SARS-CoV; Toll-like Receptor (TLR); HIV; Antibiotic |
